Onderneming Eisai Co., Ltd.

4523

JP3160400002

Farmaceutische producten

Analistenconsensus

Vakgebied

Verkoop per activiteit

Verkoop per regio

Managers

Besturend

Aandelenklasse

Aandeelhouders

Participaties

Bedrijfsgegevens

Bedrijven van de groep

Sector

Verkoop per activiteit

Verkoop per regio

Ratings voor Eisai Co., Ltd.

Herzieningen van WPA

Kwartaalwinst - Afwijkingspercentage

Sector Farmaceutische producten - Andere

Beurs gesloten - Japan Exchange Andere beurzen 08:00:00 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6.259 ^JPY	+2,79%		+7,47%	-11,25%

24/04	Biogen verslaat kwartaalwinstramingen, verkoop Alzheimer medicijnen stijgt	RE
23/04	Medicijn tegen Alzheimer in VS vertraagd door scepticisme artsen	RE

Eisai Company is gespecialiseerd in de productie en marketing van farmaceutische producten. De netto-omzet is als volgt over de productfamilie verdeeld:
- farmaceutische producten (87,7%): voorgeschreven geneesmiddelen, gezondheidsproducten, enz;
- overige (12,3%): voedingsadditieven, chemische producten, enz.
De netto-omzet is geografisch als volgt verdeeld: Japan (46,2%), Europa (19,5%), Noord- en Zuid-Amerika (15,5%), China (10,3%) en overige (8,4%).

Aantal werknemers: 11 076

JPY in miljoen	2022	Gewicht	2023	Gewicht	Delta
Pharmaceutical 91,9 %	626 281	82,8 %	684 434	91,9 %	+9,29%
Other 8,1 %	129 945	17,2 %	59 969	8,1 %	-53,85%

JPY in miljoen	2022	Gewicht	2023	Gewicht	Delta
Japan 33,6 %	243 385	32,2 %	250 327	33,6 %	+2,85%
Americas 32,1 %	226 719	30,0 %	239 293	32,1 %	+5,55%
China 14,6 %	106 592	14,1 %	108 562	14,6 %	+1,85%
Europe 11,6 %	126 745	16,8 %	86 026	11,6 %	-32,13%
Other 8,1 %	52 784	7,0 %	60 195	8,1 %	+14,04%

Managers	Titel	Leeftijd	Van
Haruo Naito CEO	Chief Executive Officer	76	01-10-75
Mitsuru Shomon DFI	Director of Finance/CFO	-	-
Makoto Hoketsu CTO	Chief Tech/Sci/R&D Officer	-	-
Yasushi Okada COO	Chief Operating Officer	65	01-04-81
Yosuke Akita CMP	Compliance Officer	59	01-04-89
Yoshiteru Kato BRD	Director/Board Member	64	01-04-88
Hideki Hayashi BRD	Director/Board Member	66	01-04-81
Hiroyuki Kato BRD	Director/Board Member	66	01-04-82
Masatomi Akana IRC	Investor Relations Contact	57	01-04-90
Sayoko Sasaki IRO	Public Communications Contact	55	01-04-91

Besturend	Titel	Leeftijd	Van
Haruo Naito CEO	Chief Executive Officer	76	01-10-75
Fumihiko Ike BRD	Director/Board Member	71	01-06-21
Toru Moriyama BRD	Director/Board Member	69	-
Hideki Hayashi BRD	Director/Board Member	66	01-04-81
Ryota Miura BRD	Director/Board Member	49	01-06-21
Yuko Yasuda BRD	Director/Board Member	62	-
Yoshiteru Kato BRD	Director/Board Member	64	01-04-88
Hideyo Uchiyama BRD	Director/Board Member	71	01-06-18
Yumiko Miwa BRD	Director/Board Member	58	01-06-20
Clive Richard Thornley BRD	Director/Board Member	59	17-06-22

	Stemming	Aantal	Vrij verhandelbaar	Bedrijfseigen aandelen	Drijvend Totaal
Aandeel A	0	296 566 949	278 292 124 ( 93,84 %)	9 530 708 ( 3,214 %)	93,84 %

Naam	Aandelen	%	Totale waarde
Wellington Management Co. LLP 6,998 %	20 752 870	6,998 %	852 M ¥
Government of Japan 5,039 %	14 945 200	5,039 %	614 M ¥
EISAI CO., LTD. 3,214 %	9 530 200	3,214 %	391 M ¥
Nikko Asset Management Co., Ltd. 2,843 %	8 432 400	2,843 %	346 M ¥
Nippon Life Insurance Co. 2,192 %	6 500 000	2,192 %	267 M ¥
Mitsubishi UFJ Asset Management Co., Ltd. 1,622 %	4 810 600	1,622 %	198 M ¥
RESONA HOLDINGS, INC. 1,619 %	4 800 000	1,619 %	197 M ¥
The Naito Foundation 1,420 %	4 212 000	1,420 %	173 M ¥
TOKIO MARINE HOLDINGS, INC. 0,5829 %	1 728 796	0,5829 %	71 M ¥
MS&AD INSURANCE GROUP HOLDINGS, INC. 0,5731 %	1 699 673	0,5731 %	70 M ¥

Naam	Aandelen	%	Totale waarde
RhumbLine Advisers LP 0,001223 %	14 510	0,001223 %	149 351 ¥
GAMMA Investing LLC 0,000051 %	602	0,000051 %	6 196 ¥

Naam	Aandelen	%	Totale waarde
EISAI CO., LTD. 3.21%	9 530 200	3.21%	391 421 706 $
MATSUKIYOCOCOKARA & CO. 1.97%	8 445 000	1.97%	136 123 266 $
KISSEI PHARMACEUTICAL CO., LTD. 0.96%	474 000	0.96%	11 071 327 $
COGSTATE LIMITED 6.85%	11 738 243	6.85%	10 338 340 $
ROIVANT SCIENCES LTD. 0.11%	874 957	0.11%	9 222 047 $
VITAL KSK HOLDINGS, INC. 1.24%	642 154	1.24%	5 329 185 $
LIFENET INSURANCE COMPANY 0.43%	349 000	0.43%	3 486 657 $
HOKUYAKU TAKEYAMA HOLDINGS,INC. 2.24%	546 000	2.24%	3 138 659 $
MEDIPAL HOLDINGS CORPORATION 0.06%	134 748	0.06%	2 065 580 $
ASTENA HOLDINGS CO., LTD. 0.14%	56 608	0.14%	184 024 $

Eisai Co., Ltd.

4-6-10 Koishikawa Bunkyo-Ku

112-8088, Tokyo

+81 3 3817 3700

http://www.eisai.co.jp

Naam	Categorie en sector
Eisai Ltd. (United Kingdom) Eisai Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Eisai Ltd. (United Kingdom) is a pharmaceutical company based in Hatfield, UK. Part of Eisai Co., Ltd., Eisai Ltd. prioritizes patients and their families by continually improving the benefits that healthcare can provide. The British company was founded in 1988 and Gary Bryan Hendler has been the CEO of the company since 2008.	Pharmaceuticals: Major
Eisai Pharmaceuticals India Pvt Ltd. Eisai Pharmaceuticals India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., Eisai Pharmaceuticals India Pvt Ltd. is an Indian company that manufactures and exports drug substances. The private company is based in Visakhapatnam, India. The company was founded in 2007. The CEO is Sanjit Singh Lamba.	Pharmaceuticals: Major
Eisai Manufacturing Ltd. Eisai Manufacturing Ltd. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., Eisai Manufacturing Ltd. is a pharmaceutical company based in Hatfield, UK. The British company's focus is on developing new medicines for neglected tropical diseases and malaria, improving access to medicines for non-communicable diseases, and promoting sustainability. Eisai Manufacturing is committed to funding the 3rd phase of health innovative technology fund activities. The private company's official corporate website provides information on their initiatives and HHC concept.	Pharmaceuticals: Major

Trading rating

Beleggingsrating

ESG Refinitiv

A-

Meer adviezen

Verkoop

Koop

Gemiddeld advies

Accumuleren

Aantal analisten

Laatste slotkoers

6.089 JPY

Gemiddelde koersdoel

8.193 JPY

Spread / Gemiddelde doel

+34,55%

Consensus

Bedrijfscijfers

De agenda van het bedrijf

Gezondheidszorg

Farmaceutisch en medisch onderzoek

Farmaceutische producten

Farmaceutische producten

Farmaceutische producten - Andere

	Vaira. 1 jan.	Kapi.
EISAI CO., LTD.	-11,25%	11,26 mld.
NOVO NORDISK A/S	+23,16%	562 mld.
JOHNSON & JOHNSON	-5,24%	358 mld.
MERCK & CO., INC.	+16,49%	322 mld.
ABBVIE INC.	+8,28%	297 mld.
ASTRAZENECA PLC	+12,38%	219 mld.
NOVARTIS AG	+6,48%	199 mld.
ROCHE HOLDING AG	-9,98%	196 mld.
PFIZER, INC.	-8,75%	149 mld.
AMGEN INC.	-5,21%	146 mld.

Farmaceutische producten - Andere